Tumor Research Lab, Cancer Hospital of Shantou University Medical College, 515041, Shantou, People's Republic of China.
Cytotechnology. 2010 Oct;62(5):431-8. doi: 10.1007/s10616-010-9296-7. Epub 2010 Sep 1.
Celecoxib is a selective cyclooxygenase-2 (COX-2) inhibitor with antitumor and antiangiogenic activities. To investigate the effects of celecoxib on nasopharyngeal carcinoma (NPC), HNE-1 cells were treated with celecoxib at various concentrations. MTT assay, migration assay and invasion assay were performed to observe the inhibitory activity of celecoxib on HNE-1 cells. Additionally, VEGF-A expression and radiation survival of NPC cell were also examined after treatment with celecoxib. Celecoxib treatment presented an anti-proliferation function in a time and dose-dependent manner on HNE-1 cells which highly express COX-2 protein. Celecoxib also displayed an obvious inhibitory activity on invasive capacity of NPC cells. Moreover, the celecoxib's effects to suppress VEGF-A expression and enhance radiosensitivity were detected in HNE-1 cells. These findings implicate that application of celecoxib may be an effective strategy for NPC therapy.
塞来昔布是一种选择性环氧化酶-2(COX-2)抑制剂,具有抗肿瘤和抗血管生成活性。为了研究塞来昔布对鼻咽癌(NPC)的影响,用不同浓度的塞来昔布处理 HNE-1 细胞。通过 MTT 试验、迁移试验和侵袭试验观察塞来昔布对 HNE-1 细胞的抑制活性。此外,还检测了塞来昔布处理后 NPC 细胞中 VEGF-A 表达和辐射存活情况。结果显示,在高表达 COX-2 蛋白的 HNE-1 细胞中,塞来昔布呈时间和剂量依赖性的抗增殖作用。塞来昔布对 NPC 细胞的侵袭能力也有明显的抑制作用。此外,在 HNE-1 细胞中检测到塞来昔布抑制 VEGF-A 表达和增强放射敏感性的作用。这些发现表明,塞来昔布的应用可能是 NPC 治疗的一种有效策略。